SCHEMBL1256554

SCHEMBL1256554

CC(=O)Nc1nc(-c2ccco2)c(-c2cc[n+]([O-])cc2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 8/20 0.54
HSP90AA1 P07900 1/20 0.54
ALDH1A1 P00352 6/20 0.53
MAPT P10636 6/20 0.53
KDM4E B2RXH2 5/20 0.53
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
POLB P06746 5/20 0.53
LMNA P02545 3/20 0.53
HPGD P15428 3/20 0.53
BLM P54132 2/20 0.53
USP2 O75604 2/20 0.52
PKM P14618 2/20 0.51
PLA2G1B P04054 1/20 0.51
ATG4B Q9Y4P1 1/20 0.51
GAA P10253 2/20 0.48
ATM Q13315 1/20 0.47
NPSR1 Q6W5P4 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ADORA2A P29274 6/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1256617 0.87 MAPT (0.61) L3MBTL1HSP90AA1ALDH1A1MAPTKDM4E
SCHEMBL1256053 0.85 ADORA2B (0.60) L3MBTL1HSP90AA1ALDH1A1MAPTKDM4E
SCHEMBL6545521 0.78 ALDH1A1 (0.54) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL6546346 0.77 MAPT (0.59) L3MBTL1ALDH1A1MAPTKDM4EMEN1
SCHEMBL6546857 0.77 MAPT (0.81) L3MBTL1ALDH1A1MAPTKDM4EMEN1
SCHEMBL1256580 0.77 MEN1 (0.55) L3MBTL1HSP90AA1ALDH1A1MAPTKDM4E
SCHEMBL6545671 0.76 MAPT (0.58) L3MBTL1ALDH1A1MAPTKDM4EMEN1
SCHEMBL1256531 0.76 L3MBTL1 (0.55) L3MBTL1HSP90AA1ALDH1A1MAPTKDM4E
SCHEMBL6545796 0.76 MAPT (0.57) L3MBTL1ALDH1A1MAPTKDM4EMEN1
SCHEMBL3572613 0.74 PIK3CG (0.60) L3MBTL1HSP90AA1ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 EP disclosed
EP-3002283-B1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO LTD (JP) 2017-06-14 EP disclosed
EP-3002283-A1 THIAZOLE DERIVATIVES Kyowa Hakko Kirin Co., Ltd. (JP) 2016-04-06 EP disclosed
EP-1700856-B1 THIAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2015-11-11 EP disclosed
US-8889718-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-11-18 US disclosed
US-20130267509-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-10-10 US disclosed
US-8420827-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-04-16 US disclosed
US-20110105486-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-05-05 US disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 US disclosed
US-7880013-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-01 US disclosed
CN-1902196-B Thiazole derivatives KYOWA HAKKO KOGYO KK 2010-12-29 CN disclosed
US-20100256361-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
US-7718808-B2 Thiazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-05-18 US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 EP disclosed
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-10 US disclosed
CN-1902196-A Thiazole derivatives KYOWA HAKKO KOGYO KK (JP) 2007-01-24 CN disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267509-A1 THIAZOLE DERIVATIVES THRA, CHD8, CYP2C8 L3MBTL1 436/4885HSP90AA1 1557/4885ALDH1A1 1344/4885
US-20110105486-A1 THIAZOLE DERIVATIVES CHD8, CYP2C8, THRA L3MBTL1 702/4885HSP90AA1 1930/4885ALDH1A1 769/4885
US-20100256361-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, ADORA1 L3MBTL1 2618/4885HSP90AA1 3782/4885ALDH1A1 1290/4885
US-20070105919-A1 adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders ADORA2A, ADORA3, ADORA1 L3MBTL1 2473/4885HSP90AA1 4374/4885ALDH1A1 2843/4885
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 L3MBTL1 1732/4885HSP90AA1 2054/4885ALDH1A1 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.